<DOC>
	<DOC>NCT01832870</DOC>
	<brief_summary>This is a clinical trial designed to quantify the immune response and determine the tolerability and side effects of sipuleucel-T when given in combination with ipilimumab for patients with advanced prostate cancer.</brief_summary>
	<brief_title>Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Subjects with advanced prostate cancer who are eligible to receive sipuleucelT in accordance with FDA approved labeling of sipuleucelT Subjects must understand and sign an informed consent form Subjects who are not eligible to receive sipuleucelT</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>